Wilms' Tumor 1 (WT1): The Vaccine for Cancer-Reference-Cited by-同舟云学术

Wilms' Tumor 1 (WT1): The Vaccine for Cancer

Published:2020-11-01 Issue:4 Volume:3 Page:165-171
ISSN:2590-017X
Container-title:Journal of Immunotherapy and Precision Oncology
language:en
Short-container-title:

Author:

Hein Kyaw Zaw¹,Yao Shuyang²³,Fu Siqing²

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3. Department of Thoracic Surgery, Xuanwu Hospital Capital Medical University, Beijing, China

Abstract

ABSTRACT Vaccines have been used to fight and protect against infectious diseases for centuries. With the emergence of immunotherapy in cancer treatment, researchers began investigating vaccines that could be used against cancer, especially against tumors that are resistant to conservative chemotherapy, surgery, and radiotherapy. The Wilms' tumor 1 (WT1) protein is immunogenic, has been detected in almost all types of malignancies, and has played a significant role in prognosis and disease monitoring. In this article, we review recent developments in the treatment of various types of cancers with the WT1 cancer vaccine; we also discuss theoretic considerations of various therapeutic approaches, which were based on preclinical and clinical data.

Publisher

Innovative Healthcare Institute

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://meridian.allenpress.com/innovationsjournals-JIPO/article-pdf/3/4/165/2871045/i2590-017x-3-4-165.pdf

Reference68 articles.

1. Anguille S, Smits EL, Bryant C, et al. Dendritic cells as pharmacological tools for cancer immunotherapy.Pharmacologic Rev.2015; 67: 731–753.

2. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy.Lancet Oncol.2014; 15: e257–e267.

3. Mackall CL, Merchant MS, Fry TJ. Immune-based therapies for childhood cancer.Nat Rev Clin Oncol.2014; 11: 693.

4. Melief CJM, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines.J Clin Invest.2015; 125: 3401–3412.

5. Ceppi F, Beck-Popovic M, Bourquin JP, Renella R. Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.Eur J Pediatr.2017; 176: 1163–1172.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer immunotherapy of Wilms tumor: a narrative review;Future Oncology;2024-09-05

2. Crosstalk between genomic variants and DNA methylation in FLT3 mutant acute myeloid leukemia;Briefings in Functional Genomics;2024-06-30

3. Exploring Immunological Effects and Novel Immune Adjuvants in Immunotherapy for Salivary Gland Cancers;Cancers;2024-03-19

4. Glioblastoma vaccines: past, present, and opportunities;eBioMedicine;2024-02

5. Wilms’ tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP;PLOS Pathogens;2024-01-08